Back to Search
Start Over
The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
- Source :
- Alzheimer's & Dementia, 11(2), 195-206. Elsevier Science, Alzheimer's and Dementia, Vol. 11, No 2 (2015) pp. 195-206e1, Alzheimers & Dementia, 11(2), 195-206. Elsevier, Alzheimers & Dementia, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Alzheimer's & Dementia, 11, 2, pp. 195-206.e1, Alzheimer's and dementia 11(2), 195-206.e1 (2015). doi:10.1016/j.jalz.2014.06.006, Alzheimer's & Dementia, 11, 195-206.e1, Bocchetta, M, Galluzzi, S, Kehoe, P G, Aguera, E, Bernabei, R, Bullock, R, Ceccaldi, M, Dartigues, J F, de Mendonca, A, Didic, M, Eriksdotter, M, Felician, O, Frolich, L, Gertz, H J, Hallikainen, M, Hasselbalch, S G, Hausner, L, Heuser, I, Jessen, F, Jones, R W, Kurz, A, Lawlor, B, Lleo, A, Martinez-Lage, P, Mecocci, P, Mehrabian, S, Monsch, A, Nobili, F, Nordberg, A, Rikkert, M O, Orgogozo, J M, Pasquier, F, Peters, O, Salmon, E, Sanchez-Castellano, C, Santana, I, Sarazin, M, Traykov, L, Tsolaki, M, Visser, P J, Wallin, A K, Wilcock, G, Wilkinson, D, Wolf, H, Yener, G, Zekry, D & Frisoni, G B 2015, ' The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey ', Alzheimers & Dementia, vol. 11, no. 2, pp. 195-206 . https://doi.org/10.1016/j.jalz.2014.06.006, Alzheimer's & Dementia
- Publication Year :
- 2015
-
Abstract
- We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid position emission tomography [PET], cerebrospinal fluid [CSF] A beta 42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
- Subjects :
- Oncology
Pathology
Alzheimer`s disease Donders Center for Medical Neuroscience [Radboudumc 1]
Neurology
pathology [Cognitive Dysfunction]
Epidemiology
cerebrospinal fluid [Amyloid beta-Peptides]
Practice Patterns
etiology [Cognitive Dysfunction]
Alzheimer's disease
Biomarkers
Diagnosis
Mild cognitive impairment
Alzheimer Disease
Amyloid beta-Peptides
Atrophy
Brain
Europe
Fluorodeoxyglucose F18
Internet
Magnetic Resonance Imaging
Mild Cognitive Impairment
Peptide Fragments
Positron-Emission Tomography
Radiopharmaceuticals
Surveys and Questionnaires
tau Proteins
Practice Patterns, Physicians'
Neurology (clinical)
Developmental Neuroscience
Cellular and Molecular Neuroscience
Psychiatry and Mental Health
Geriatrics and Gerontology
Health Policy
Medicine (all)
pathology [Alzheimer Disease]
ddc:616.89
Cerebrospinal fluid
pathology [Brain]
medicine.diagnostic_test
Amyloidosis
diagnosis [Alzheimer Disease]
complications [Alzheimer Disease]
amyloid beta-protein (1-42)
3. Good health
cerebrospinal fluid [Alzheimer Disease]
cerebrospinal fluid [Cognitive Dysfunction]
Psychiatry and Mental health
cerebrospinal fluid [Biomarkers]
Positron emission tomography
Biomarker (medicine)
Alzheimer's disease, Biomarkers, Diagnosis, Mild cognitive impairment
medicine.medical_specialty
MAPT protein, human
Internal medicine
medicine
Cognitive Dysfunction
ddc:610
cerebrospinal fluid [Peptide Fragments]
Vascular dementia
diagnostic imaging [Brain]
Physicians'
business.industry
medicine.disease
diagnosis [Cognitive Dysfunction]
cerebrospinal fluid [tau Proteins]
business
Subjects
Details
- Language :
- English
- ISSN :
- 15525260
- Database :
- OpenAIRE
- Journal :
- Alzheimer's & Dementia, 11(2), 195-206. Elsevier Science, Alzheimer's and Dementia, Vol. 11, No 2 (2015) pp. 195-206e1, Alzheimers & Dementia, 11(2), 195-206. Elsevier, Alzheimers & Dementia, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Alzheimer's & Dementia, 11, 2, pp. 195-206.e1, Alzheimer's and dementia 11(2), 195-206.e1 (2015). doi:10.1016/j.jalz.2014.06.006, Alzheimer's & Dementia, 11, 195-206.e1, Bocchetta, M, Galluzzi, S, Kehoe, P G, Aguera, E, Bernabei, R, Bullock, R, Ceccaldi, M, Dartigues, J F, de Mendonca, A, Didic, M, Eriksdotter, M, Felician, O, Frolich, L, Gertz, H J, Hallikainen, M, Hasselbalch, S G, Hausner, L, Heuser, I, Jessen, F, Jones, R W, Kurz, A, Lawlor, B, Lleo, A, Martinez-Lage, P, Mecocci, P, Mehrabian, S, Monsch, A, Nobili, F, Nordberg, A, Rikkert, M O, Orgogozo, J M, Pasquier, F, Peters, O, Salmon, E, Sanchez-Castellano, C, Santana, I, Sarazin, M, Traykov, L, Tsolaki, M, Visser, P J, Wallin, A K, Wilcock, G, Wilkinson, D, Wolf, H, Yener, G, Zekry, D & Frisoni, G B 2015, ' The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey ', Alzheimers & Dementia, vol. 11, no. 2, pp. 195-206 . https://doi.org/10.1016/j.jalz.2014.06.006, Alzheimer's & Dementia
- Accession number :
- edsair.doi.dedup.....0ff782b833d353e1ac30f82e3ca992f2